DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Physician-Patient Communication and Expectations Regarding Ovarian Cancer Prognosis

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2016-05-11

Last Posted Date: 2020-04-02

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 50

Registration Number: NCT02769546

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Cardiotoxicity of Radiation Therapy (CTRT)

Completed

Conditions: Breast Cancer
Mediastinal Lymphomas
Lung Cancer

First Posted Date: 2016-05-11

Last Posted Date: 2019-01-09

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 147

Registration Number: NCT02769299

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

A Non-Invasive Cervical Cancer Screening Modality: A Pilot Study

Not Applicable

Terminated

Conditions: Women With Abnormal Pap Smears

First Posted Date: 2016-05-10

Last Posted Date: 2020-05-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 4

Registration Number: NCT02767726

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Clinical Utility of a Low-Cost Hand-Held Breast Scanner

Not Applicable

Completed

Conditions: Symptomatic Breast Lump

First Posted Date: 2016-05-05

Last Posted Date: 2021-08-16

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 89

Registration Number: NCT02762565

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Assessing the Impact of Electronic Capture of Patient Reported Outcomes in Radiation Oncology

Completed

Conditions: Patients With Lung, Breast, Head and Neck, or Pelvic Malignancies

Interventions: Other: Survey

First Posted Date: 2016-04-29

Last Posted Date: 2021-06-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 75

Registration Number: NCT02756767

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710

Completed

Conditions: Bladder Cancer

First Posted Date: 2016-04-29

Last Posted Date: 2023-08-07

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 634

Registration Number: NCT02756637

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Adherence to Aromatase Inhibitors: The Role of Partners

Completed

Conditions: Breast Cancer Survivors

First Posted Date: 2016-04-28

Last Posted Date: 2019-07-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 40

Registration Number: NCT02753985

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

FDG PET/CT in Lung Cancer Staging

Not Applicable

Active, not recruiting

Conditions: Non-Small Cell Lung Cancer (NSCLC)

Interventions: Radiation: FDG PET/CT

First Posted Date: 2016-04-14

Last Posted Date: 2024-11-13

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 30

Registration Number: NCT02738398

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

Not Applicable

Recruiting

Conditions: Breast Cancer

Interventions: Other: Research Blood Collection

First Posted Date: 2016-04-08

Last Posted Date: 2024-07-30

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 600

Registration Number: NCT02732171

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver

Phase 2

Completed

Conditions: Neuroendocrine Tumor, Malignant
Liver Metastases

Interventions: Device: Bland Embolization
Combination Product: Drug Eluting Beads Embolization
Combination Product: Transarterial chemoembolization

First Posted Date: 2016-03-31

Last Posted Date: 2025-01-06

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 162

Registration Number: NCT02724540

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Stanford University, Standford, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 10 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy